Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504

Shoushtari, Alexander N.; Khan, Shaheer; Komatsubara, Kimberly; Feun, Lynn; Acquavella, Nicolas; Singh-Kandah, Shahnaz; Negri, Tiffany; Nesson, Alexandra; Abbate, Kelly; Cremers, Serge; Musi, Elgilda; Ambrosini, Grazia; Lee, Shing; Schwartz, Gary K.; Carvajal, Richard D.

doi:10.3390/cancers17183018

Open AccessCorrection

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504

by

Alexander N. Shoushtari

^1,*,†

,

Shaheer Khan

^2,†,

Kimberly Komatsubara

^2,†,

Lynn Feun

³,

Nicolas Acquavella

³,

Shahnaz Singh-Kandah

²,

Tiffany Negri

²,

Alexandra Nesson

²,

Kelly Abbate

¹,

Serge Cremers

²,

Elgilda Musi

²,

Grazia Ambrosini

²,

Shing Lee

⁴,

Gary K. Schwartz

² and

Richard D. Carvajal

²

¹

Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

²

Columbia University Irving Medical Center, New York, NY 10032, USA

³

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA

⁴

Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA

^*

Author to whom correspondence should be addressed.

^†

Authors contributed equally to this work.

Cancers 2025, 17(18), 3018; https://doi.org/10.3390/cancers17183018

Submission received: 8 August 2025 / Accepted: 8 September 2025 / Published: 16 September 2025

Download

Browse Figure

Versions Notes

Figure

In the original publication [1], there was a mistake in Figure 3 in which an incorrect Western blot was inadvertently inserted under subject 001-17. Source files were reviewed, and the correct Western blot was identified. The correct Figure 3 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

Shoushtari, A.N.; Khan, S.; Komatsubara, K.; Feun, L.; Acquavella, N.; Singh-Kandah, S.; Negri, T.; Nesson, A.; Abbate, K.; Cremers, S.; et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504. [Google Scholar] [CrossRef] [PubMed]

Figure 3. Western blot analysis of PKC and PI3Kα-AKT-mTOR pathway inhibition. Paired tumor biopsies were assessed by Western blot for pAKT, pS6, pERK1/2, pMARCKS, and the respective total proteins. GAPDH was used as a loading control. Clinical outcomes for these respective patients are listed. Protein quantitation of the pre-treatment (left) and post-treatment (right) Western blot analysis performed with Image J. The pre-treatment sample expression level represents a baseline of 100%, with the post-treatment sample expression levels relative to this baseline. Bar plots represent pAKT/total AKT, pS6/total S6, pERK1/2/ total ERK1/2, and pMARCKS/MARCKS, respectively.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Shoushtari, A.N.; Khan, S.; Komatsubara, K.; Feun, L.; Acquavella, N.; Singh-Kandah, S.; Negri, T.; Nesson, A.; Abbate, K.; Cremers, S.; et al. Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504. Cancers 2025, 17, 3018. https://doi.org/10.3390/cancers17183018

AMA Style

Shoushtari AN, Khan S, Komatsubara K, Feun L, Acquavella N, Singh-Kandah S, Negri T, Nesson A, Abbate K, Cremers S, et al. Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504. Cancers. 2025; 17(18):3018. https://doi.org/10.3390/cancers17183018

Chicago/Turabian Style

Shoushtari, Alexander N., Shaheer Khan, Kimberly Komatsubara, Lynn Feun, Nicolas Acquavella, Shahnaz Singh-Kandah, Tiffany Negri, Alexandra Nesson, Kelly Abbate, Serge Cremers, and et al. 2025. "Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504" Cancers 17, no. 18: 3018. https://doi.org/10.3390/cancers17183018

APA Style

Shoushtari, A. N., Khan, S., Komatsubara, K., Feun, L., Acquavella, N., Singh-Kandah, S., Negri, T., Nesson, A., Abbate, K., Cremers, S., Musi, E., Ambrosini, G., Lee, S., Schwartz, G. K., & Carvajal, R. D. (2025). Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504. Cancers, 17(18), 3018. https://doi.org/10.3390/cancers17183018

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI